MUC16 and cancer: Abnormal sialylation has been linked to malignant transformation [5], and several sialylated glycoproteins, including prostate-specific antigen (PSA), cancer antigen 125 (CA125), and thyroglobulin, are utilized as clinical cancer biomarkers [6].